Payment overview · 2025
General Payments
$702.05
28 reported records · 15 companies
Healthcare provider profile · identity verified
Lisa Ma, MD
Allopathic & Osteopathic Physicians|Family Medicine · LOS ANGELES, CA · NPI 1639125487
Verified facts
What the public records show
CMS Open Payments records show Lisa Ma, MD received $702.05 in general payments during 2025 across 28 reported records.
ABBVIE INC. accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lumigan by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Arexvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $130.95 | 18.6% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $86.69 | 12.3% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $80.89 | 11.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $78.02 | 11.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.17 | 8.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.72 | 5.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.53 | 5.8% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $28.61 | 4.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.73 | 3.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.16 | 3.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.70 | 3.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.58 | 3.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.15 | 3.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.06 | 2.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.09 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $702.05 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.27 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $86.69 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.17 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $53.49 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $52.89 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $51.13 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $28.61 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $27.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
52 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 682 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 407 | 77 |
| Gabapentin | Gabapentin | 407 | 67 |
| Losartan Potassium | Losartan Potassium | 276 | 58 |
| Xarelto | Rivaroxaban | 242 | 22 |
| Famotidine | Famotidine | 226 | 47 |
| Eliquis | Apixaban | 195 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 195 | 38 |
| Metformin Hcl | Metformin Hcl | 185 | 49 |
| Memantine Hcl | Memantine Hcl | 170 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 33 |
| Carvedilol | Carvedilol | 164 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 24 |
| Donepezil Hcl | Donepezil Hcl | 154 | 26 |
| Lisinopril | Lisinopril | 152 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 16 |
| Januvia | Sitagliptin Phosphate | 106 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 105 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 13 |
| Tramadol Hcl | Tramadol Hcl | 99 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 16 |
| Jardiance | Empagliflozin | 92 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 84 | 14 |
| Mirtazapine | Mirtazapine | 84 | 20 |
| Potassium Chloride | Potassium Chloride | 83 | 25 |
| Trazodone Hcl | Trazodone Hcl | 80 | 18 |
| Baclofen | Baclofen | 79 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 72 | suppressed |
| Ozempic | Semaglutide | 72 | 15 |
| Furosemide | Furosemide | 70 | 21 |
| Clonidine Hcl | Clonidine Hcl | 69 | 24 |
| Entresto | Sacubitril/Valsartan | 69 | suppressed |
| Levetiracetam | Levetiracetam | 66 | 11 |
| Spironolactone | Spironolactone | 64 | 13 |
| Lactulose | Lactulose | 63 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 15 |
| Sevelamer Carbonate | Sevelamer Carbonate | 56 | suppressed |
| Simvastatin | Simvastatin | 54 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 52 | 52 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 52 | 15 |
| Finasteride | Finasteride | 51 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 51 | 26 |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 40 |
| Omeprazole | Omeprazole | 50 | 22 |
| Liothyronine Sodium | Liothyronine Sodium | 49 | 13 |
| Lorazepam | Lorazepam | 48 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 12 |
| Celecoxib | Celecoxib | 43 | 11 |
| Fluconazole | Fluconazole | 42 | 26 |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Prednisone | Prednisone | 41 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 40 | 19 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 11 |
| Latanoprost | Latanoprost | 38 | suppressed |
| Carisoprodol | Carisoprodol | 37 | suppressed |
| Enulose | Lactulose | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Progesterone | Progesterone, Micronized | 37 | 12 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 15 |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Azithromycin | Azithromycin | 31 | 27 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 18 |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 20 | suppressed |
| Humulin R | Insulin Regular, Human | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 12 |
| Ursodiol | Ursodiol | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Ssd | Silver Sulfadiazine | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Belbuca | Buprenorphine Hcl | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | 13 |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Rifampin | Rifampin | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Topiramate Er | Topiramate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $702.05 · 28 records | ABBVIE INC. | AREXVY, CAPVAXIVE, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, INGREZZA, KRYSTEXXA, Kerendia, Korlym, MINIMED 780G, MOUNJARO, Ozempic, QULIPTA, ROTATEQ, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VAQTA, VAXNEUVANCE, VERQUVO, VOWST, VRAYLAR, XIFAXAN, ZENPEP, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error